Supernus Pharmaceuticals, Inc. (SUPN): Revenue
$718.95M
Year ended 2025-12-31
$830.44M
Trailing 12 months to 2026-06-30
+2.5%
3-year compound annual growth
+6.7%
5-year compound annual growth
+17.2%
10-year compound annual growth
| Period ended | Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $718.95M | +8.6% | 2026-03-02, From 2025-01-01 |
| 2024-12-31 | $661.82M | +8.9% | 2026-03-02, From 2024-01-01 |
| 2023-12-31 | $607.52M | -8.9% | 2026-03-02, From 2023-01-01 |
| 2022-12-31 | $667.24M | +15.1% | 2025-02-25, From 2022-01-01 |
| 2021-12-31 | $579.77M | +11.4% | 2023-03-09, From 2021-01-01 |
| 2020-12-31 | $520.40M | +32.5% | 2023-03-09, From 2020-01-01 |
| 2019-12-31 | $392.75M | -3.9% | 2022-04-13, From 2019-01-01 |
| 2018-12-31 | $408.90M | +35.3% | 2021-03-08, From 2018-01-01 |
| 2017-12-31 | $302.24M | +40.6% | 2020-02-28, From 2017-01-01 |
| 2016-12-31 | $215.00M | +45.8% | 2019-03-01, From 2016-01-01 |
| 2015-12-31 | $147.47M | +59.1% | 2018-03-01, From 2015-01-01 |
| 2014-12-31 | $92.68M | +671.1% | 2017-03-16, From 2014-01-01 |
| 2013-12-31 | $12.02M | +712.1% | 2017-01-20, From 2013-01-01 |
| 2012-12-31 | $1.48M | +84.3% | 2015-03-12, From 2012-01-01 |
| 2011-12-31 | $803.0K | +657.5% | 2014-03-21, From 2011-01-01 |
| 2010-12-31 | $106.0K | n/a | 2013-03-15, From 2010-01-01 |
Revenue at similar companies
| Company | Year ended | Revenue | Change YoY |
|---|---|---|---|
| Supernus Pharmaceuticals, Inc. (SUPN) | 2025-12-31 | $718.95M | +8.6% |
| Amphastar Pharmaceuticals, Inc. (AMPH) | 2025-12-31 | $719.89M | -1.7% |
| Pacira BioSciences, Inc. (PCRX) | 2025-12-31 | $726.41M | +3.6% |
| Emergent BioSolutions Inc. (EBS) | 2025-12-31 | $742.90M | -28.8% |
| Corcept Therapeutics Inc (CORT) | 2025-12-31 | $761.41M | +12.8% |
| Kiniksa Pharmaceuticals International, plc (KNSA) | 2025-12-31 | $677.56M | +60.1% |
| Ultragenyx Pharmaceutical Inc. (RARE) | 2025-12-31 | $673.00M | +20.2% |
| Collegium Pharmaceutical, Inc (COLL) | 2025-12-31 | $780.57M | +23.6% |
| Axsome Therapeutics, Inc. (AXSM) | 2025-12-31 | $638.50M | +65.5% |
Compare SUPN, AMPH, PCRX, EBS side by side · Screen every company in Pharmaceutical Preparations ↗